secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2022-04-21T23:59:59+00:00
Accession:  0001104659-22-047977
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck ends exclusion of upfront/milestone payments and pre-approval asset charges from non-GAAP results
--------------------------------------------------------------------------------

- Merck will no longer exclude upfront/milestone payments and pre-approval asset acquisition charges from non-GAAP results, effective Q1 2022.
- Recast FY2021 non-GAAP EPS from continuing ops is $5.37, down from previously reported $6.02; FY2020 revised to $2.97 from $4.53.
- Change aligns with SEC staff views; does not affect Q1 2021 or Q1 2022 non-GAAP results.
- Revised non-GAAP R&D expense for full-year 2021 is $11,738M vs previously reported $10,077M (increase of $1,661M).
- The recast 2021 annual net income attributable to Merck is $13,623M vs previously $15,282M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465922047977/0001104659-22-047977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465922047977/tm2212593d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-047977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer